Literature DB >> 8419025

Comparison of hemodynamic determinants for myocardial oxygen consumption under different contractile states in human ventricle.

H Takaoka1, M Takeuchi, M Odake, Y Hayashi, K Hata, M Mori, M Yokoyama.   

Abstract

BACKGROUND: Recently, several indexes such as tension-time index (TTI), tension-time or force-time integral (FTI), rate-pressure product (RPP), pressure-work index (PWI), and systolic pressure-volume area (PVA) have been developed as predictors of myocardial oxygen consumption in experimental and clinical studies. However, it is still unclear whether these indexes are reliable predictors of myocardial oxygen consumption under various contractile states in human hearts. METHODS AND
RESULTS: We assessed the relation between TTI, FTI, RPP, PWI, and PVA and myocardial oxygen consumption per beat (VO2) in 13 patients with heart disease during volume loading. Left ventricular (LV) volume and pressure were measured simultaneously by the conductance catheter with the tipped micromanometer technique. VO2 was calculated from arterial coronary sinus oxygen content difference, and coronary sinus blood flow was measured by the thermodilution method. After z transformation of the correlation coefficients, mean z value for the VO2-PVA relation (1.83 +/- 0.60) was greater than those for the VO2-TTI relation (1.22 +/- 0.66; p < 0.005), VO2-FTI relation (1.18 +/- 0.61; p < 0.05), VO2-RPP relation (0.95 +/- 0.65; p < 0.05), and VO2-PWI relation (1.24 +/- 0.58; p < 0.05). During dobutamine infusion (5 micrograms.kg-1.min-1) in five of the 13 patients, VO2 also correlated best with PVA (z = 1.70 +/- 0.89) compared with TTI (z = 1.43 +/- 0.86), FTI (z = 1.48 +/- 0.95), RPP (z = 1.00 +/- 0.53), and PWI (z = 0.88 +/- 0.80). The contractile efficiency (38 +/- 14% to 38 +/- 20%), the reciprocal of the slope of the VO2-PVA relation, remained unchanged, whereas the VO2,PVA 0.8 (VO2 at PVA = 0.8 J per beat/100 g LV) increased from 1.48 +/- 1.16 to 2.06 +/- 1.13 J per beat/100 g LV (p < 0.05). These results show the parallel upward shift of the VO2-PVA relation during dobutamine infusion. Because increases in the VO2-intercept represent the VO2 for the increased excitation-contraction (E-C) coupling associated with the augmented contractile state, the parallelism of the VO2-PVA relation could discriminate between VO2 for mechanical work (PVA-dependent VO2) and VO2 for E-C coupling (PVA-independent VO2).
CONCLUSIONS: The results of the present study indicate that PVA is a reliable and valuable predictor of myocardial oxygen consumption under different contractile states in human hearts. The VO2-PVA relation could provide useful information about mechanoenergetics in diseased human hearts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419025     DOI: 10.1161/01.cir.87.1.59

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

1.  Myocardial twitch duration and the dependence of oxygen consumption on pressure-volume area: experiments and modelling.

Authors:  J-C Han; K Tran; A J Taberner; D P Nickerson; R S Kirton; P M F Nielsen; M-L Ward; M P Nash; E J Crampin; D S Loiselle
Journal:  J Physiol       Date:  2012-05-08       Impact factor: 5.182

2.  Angiocardiographic pressure volume loops in the analysis of right ventricular function after repair of tetralogy of Fallot.

Authors:  Anselm Uebing; Gunther Fischer; Friedrich Schmiel; Dietrich G W Onnasch; Jens Scheewe; Hans-Heiner Kramer
Journal:  Int J Cardiovasc Imaging       Date:  2005-10       Impact factor: 2.357

3.  Left ventricle haemodynamics and vaso-active hormones during graded supine exercise in healthy male subjects.

Authors:  I L Kanstrup; J Marving; N Gadsbøll; H Lønborg-Jensen; P F Høilund-Carlsen
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1995

4.  Echocardiography-based pressure-volume loop assessment in the evaluation for the effects of indoxyl sulfate on cardiovascular function.

Authors:  Masaru Obokata; Koji Kurosawa; Hideki Ishida; Kyoko Ito; Tetsuya Ogawa; Yoshitaka Ando; Masahiko Kurabayashi; Kazuaki Negishi
Journal:  J Echocardiogr       Date:  2018-07-07

5.  Relationships of high cardiac output with ventricular morphology, myocardial energetics, and energy costs in hemodialysis patients with preserved ejection fraction.

Authors:  Tomonari Harada; Masaru Obokata; Koji Kurosawa; Hidemi Sorimachi; Kuniko Yoshida; Hideki Ishida; Kyoko Ito; Tetsuya Ogawa; Yoshitaka Ando; Masahiko Kurabayashi; Kazuaki Negishi
Journal:  Int J Cardiovasc Imaging       Date:  2018-10-16       Impact factor: 2.357

6.  Disopyramide improves the balance between myocardial oxygen supply and demand in patients with hypertrophic obstructive cardiomyopathy.

Authors:  K Niki; M Sugawara; R Asano; T Oka; Y Kondoh; S Tanino; K Iwade; N Magosaki; H Kasanuki; S Hosoda
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

7.  An approach to ventricular efficiency by use of carbon 11-labeled acetate and positron emission tomography.

Authors:  H G Wolpers; A Buck; N Nguyen; P A Marcowitz; W F Armstrong; M R Starling; R Hicks; T J Mangner; M Schwaiger
Journal:  J Nucl Cardiol       Date:  1994 May-Jun       Impact factor: 5.952

8.  Comparative Hemodynamic Effects of Contemporary Percutaneous Mechanical Circulatory Support Devices in a Porcine Model of Acute Myocardial Infarction.

Authors:  Brian R Weil; Filip Konecny; Gen Suzuki; Vijay Iyer; John M Canty
Journal:  JACC Cardiovasc Interv       Date:  2016-10-26       Impact factor: 11.195

9.  A new methodology for non-invasive clinical assessment of cardiovascular system performance and of ventricular-arterial coupling during stress.

Authors:  E Nevo; M Marmor; Y Lanir; T A Weiss; A Marmor
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

10.  Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction.

Authors:  S Neubauer; M Horn; A Naumann; R Tian; K Hu; M Laser; J Friedrich; P Gaudron; K Schnackerz; J S Ingwall
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.